Toxicity

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with stage IV pancreatic cancer.

OBJECTIVES:

Primary

• To evaluate the 4-month progression-free survival (PFS) rate in patients with stage IV pancreatic cancer treated with dasatinib.

Secondary

• To evaluate the response rate (complete and partial response) in patients treated with this drug.
• To evaluate the median PFS and overall survival of patients treated with this drug.
• To study the toxicities and tolerability of this drug in these patients.
• To evaluate the impact of this drug on quality of life measures.
• To evaluate the impact of this drug on Src and FAK in peripheral blood mononuclear cells prior to and during treatment.
• To study the pre-treatment expression of various signaling molecules in the Src and STAT3 pathways and attempt to identify a relationship between these findings and the aggressiveness of the tumor or its response to treatment with dasatinib.

OUTLINE: This is a multicenter study.

Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo tumor tissue and blood sample collection periodically for correlative and biological studies. Blood samples are analyzed for phosphorylation levels of proteins, including phospho-Src, phospho-Fak, and other relevant biomarkers, by western blotting. Tumor tissue samples are analyzed for biomarkers by immunohistochemistry.

Quality of life is assessed at baseline, after every other course during treatment, and then at 1 year after treatment using the FACT-HEP questionnaire.

After completion of study treatment, patients are followed every 2 months.

DISEASE CHARACTERISTICS:

• Histologically* confirmed pancreatic cancer

  • Stage IV disease NOTE: *If biopsy was performed at an outside facility, the histology must be reviewed and confirmed by the Division of Pathology at the City of Hope

PATIENT CHARACTERISTICS:

• Karnofsky performance status 60-100%

• Life expectancy ≥ 3 months

• Platelet count ≥ 100,000/μL

• Absolute neutrophil count ≥ 1,500/μL

• Bilirubin ≤ 1.5 mg/dL

• ALT and AST ≤ 2.5 times upper limit of normal (ULN)

• Creatinine ≤ 1.5 mg/dL and/or creatinine clearance > 60 mL/min

• PT and PTT ≤ 1.5 times ULN

• Able to swallow dasatinib whole

• No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix, uterus, or bladder

• No concurrent medical condition which may increase the risk of toxicity, including any of the following:

  • Pleural or pericardial effusion of any grade
  • Clinically significant coagulation or platelet function disorder (e.g., known von Willebrand's disease)

• None of the following cardiac conditions:

  • Uncontrolled angina, congestive heart failure, or myocardial infarction within the past 6 months
  • Prolonged QTc interval (i.e., QTc > 450 msec) on electrocardiogram
  • History of clinically significant ventricular arrhythmias (i.e., ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)

• No hypokalemia or hypomagnesemia that cannot be corrected

• No severe infection requiring treatment

• Completely recovered from other concurrent illnesses, as deemed by the investigator

• Not pregnant

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• Recovered from prior major surgery

• No prior irradiation to the planned field

• No prior chemotherapy for pancreatic cancer

• At least 7 days since prior and no concurrent medications that may prolong the QT interval, including any of the following:

  • Quinidine
  • Procainamide
  • Disopyramide
  • Amiodarone
  • Sotalol
  • Ibutilide
  • Dofetilide
  • Erythromycin
  • Clarithromycin
  • Chlorpromazine
  • Haloperidol
  • Mesoridazine
  • Thioridazine
  • Pimozide
  • Cisapride
  • Bepridil
  • Droperidol
  • Methadone
  • Arsenic
  • Chloroquine
  • Domperidone
  • Halofantrine
  • Levomethadyl
  • Pentamidine
  • Sparfloxacin
  • Lidoflazine

• At least 7 days since prior and no concurrent potent CYP3A4 inhibitors

• At least 7 days since prior and no concurrent medications that directly and durably inhibit platelet function, including any of the following:

  • Aspirin or aspirin-containing combinations
  • Clopidogrel
  • Dipyridamole
  • Tirofiban
  • Dipyridamole
  • Epoprostenol
  • Eptifibatide
  • Cilostazol
  • Abciximab
  • Ticlopidine
  • Cilostazol

• No concurrent anticoagulants, including warfarin or heparin/low molecular weight heparin (e.g., danaparoid, dalteparin, tinzaparin, or enoxaparin)

  • Low-dose warfarin for prophylaxis to prevent catheter thrombosis or heparin for flushes of IV lines allowed

• No concurrent IV bisphosphonates during the first 8 weeks of dasatinib therapy

• No concurrent Hypericum perforatum (St. Johns wort)

"Other Adverse Events" include all events that were not severe adverse events regardless of grade or relation to treatment.

Adverse events recorded over a period of 13 months.

Study was terminated early due to toxicity.